Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIOPEN-Pilot01 dinutuximab beta plus induction chemotherapy in newly diagnosed high-risk neuroblastoma
2023-509673-22-00Phase 2Authorised
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Dec 2024
- Modality
- Antibody-Based Therapeutics
- Countries
- 9
01
Overview
Phase 2, open-label trial of Dinutuximab beta in neuroblastoma (2 arms), sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoint: Dose-limiting toxicities. Planned start Dec 2024; status: authorised.
02
Drugs
Dinutuximab beta
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on 2023-509673-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509673-22-00.